Article Details
Retrieved on: 2025-09-13 04:34:24
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The company has prioritized R&D in monoclonal antibodies and other biologics, a segment projected to grow at a double-digit CAGR through 2030.
Article found on: www.ainvest.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here